EuroPCR 2019 | MeRes-1: Bioresorbable Scaffolds Return with Renewed Strength

A small number of highly selected patients presents good outcomes with new bioresorbable scaffold MeRes, but much more evidence is necessary to bring back the concept.

EuroPCR 2019 | CHOICE: válvula balón expandible vs autoexpandibles en pacientes de alto riesgo

The MeRes-1 study tested the newest generation of the Meril Life Sciences bioresorbable scaffold, a device featuring thinner struts compared with Absorb (from 150 µm in Absorb to only 100 µm). Results at 3 years are relatively good, with a major event rate of just 1.87%.

The study included 107 patients treated with the sirolimus-eluting scaffold and only two of them required revascularization of the target lesion.

Moreover, in the MeRes-1 Extend study, a similar trial with 62 patients, the 2-year major adverse cardiac events (MACE) rate was 1.61%, with just one case of ischemia-driven revascularization.


Read also: EuroPCR 2019 | Most Recent TAVR Meta-Analysis: The Spectrum of Treatment Reaches All Patients.


Significantly, no cases of thrombosis were reported in any of these works.

The MeRes scaffold has already been approved in India and received CE Mark approval for Europe a few days ago.

These are promising data mainly regarding device safety in relatively simple lesions, but there is a need for further long-term evidence comparing device efficacy and safety with that of contemporary drug-eluting stents.

Original Title: MeRes-1 Extend: imaging and two-year clinical outcomes of thin-strut sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease.

Reference: Abizaid A.

Would you like to receive a weekly summary of the most recent scientific articles?

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

*

Top